- Dosing has commenced in AM1030-CREAM Phase 1/2a study for atopic dermatitis - GOTHENBURG, Sweden, Jan. 28, 2015 /PRNewswire/ -- AnaMar AB, a Swedish biopharmaceutical company building a selective ...

First-in-class, peripheral serotonin (5-HT 2B) receptor antagonist being developed as a highly selective, oral, anti-fibrotic medicine for skin and lung disorders LUND, Sweden, May 23, 2023 (GLOBE ...

AnaMar has rejigged its pipeline priorities after digging through the data from its failed Phase IIa trial. The trial missed its primary endpoint of reducing pain in people with mild to moderate ...

Lund, Sweden, 5 Feb 2024: AnaMar, a clinical-stage biotech company developing first in class anti-fibrotic 5-HT 2B receptor antagonists, announces that the European Medicines Agency (EMA) and the ...

Receptor antagonist AM1476 developed as an anti-fibrotic treatment for lung and skin disorders Receptor antagonist AM1476 developed as an anti-fibrotic treatment for lung and skin disorders AnaMar has ...

Lund-based AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, has announced that the European Medicines Agency (EMA) and the United States ...

AnaMar, a clinical-stage biotech company, announces positive results from its phase I study, and the completion of phase II enabling pre-clinical studies for its initial orphan indication in systemic ...